<p>Aura Biosciences, Inc.（納斯達克代碼：AURA - 獲取免費報告）內部人士 Conor Kilroy 於 4 月 16 日（星期三）出售了 7,162 股公司股票。該股票以平均價格 5.49 美元出售，總價值為 39,319.38 美元。出售後，該內部人士現在持有 179,313 股公司股票，價值為 984,428.37 美元。這代表其持股比例下降了 3.84%。此次出售已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
<p>獲取 <strong>Aura Biosciences</strong> 警報：</p>
<h2>Aura Biosciences 股價下跌 3.1%</h2>
<ul>
<li>3 只小盤股準備實現顯著增長</li>
</ul>
<p>在週三的交易時段，納斯達克：AURA 股價下跌 0.17 美元，跌至 5.40 美元。該股票的交易量為 138,043 股，而其平均交易量為 200,409 股。該公司的 50 日簡單移動平均為 6.85 美元，200 日簡單移動平均為 8.23 美元。Aura Biosciences, Inc.的 1 年最低價為 3.40 美元，1 年最高價為 12.38 美元。該公司的市值為 2.7122 億美元，市盈率為-3.12，貝塔值為 0.43。</p>
<p>Aura Biosciences（納斯達克：AURA - 獲取免費報告）最近於 3 月 24 日（星期一）發佈了季度財報。該公司報告季度每股收益（EPS）為-0.52 美元，低於市場共識預期的-0.43 美元，差距為-0.09 美元。研究分析師預計 Aura Biosciences, Inc.在當前財政年度將發佈-1.66 的每股收益。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近調整了對該公司的持股。Long Focus Capital Management LLC 在第四季度將其在 Aura Biosciences 的持股增加了 123.9%。Long Focus Capital Management LLC 現在擁有 2,537,774 股公司股票，價值 20,861,000 美元，在上個季度購買了 1,404,228 股。Vanguard Group Inc.在第四季度將其在 Aura Biosciences 的持股增加了 6.2%。Vanguard Group Inc.現在擁有 1,917,730 股公司股票，價值 15,764,000 美元，在上個季度購買了 112,296 股。Franklin Resources Inc.在第四季度將其在 Aura Biosciences 的持股增加了 3.2%。Franklin Resources Inc.現在擁有 1,723,063 股公司股票，價值 14,164,000 美元，在上個季度購買了 54,103 股。Levin Capital Strategies L.P.在第四季度將其在 Aura Biosciences 的持股增加了 169.1%。Levin Capital Strategies L.P.現在擁有 1,247,619 股公司股票，價值 10,255,000 美元，在上個季度購買了 783,984 股。最後，Geode Capital Management LLC 在第四季度將其在 Aura Biosciences 的持股增加了 0.4%。Geode Capital Management LLC 現在擁有 1,012,799 股公司股票，價值 8,327,000 美元，在上個季度購買了 3,972 股。機構投資者和對沖基金持有該公司 96.75% 的股票。</p>
<h2>分析師評級變動</h2>
<p>一些分析師最近對該公司發佈了報告。JMP Securities 在 3 月 26 日（星期三）的報告中將 Aura Biosciences 的目標價格設定為 19.00 美元。HC Wainwright 在 3 月 25 日（星期二）的研究報告中將 Aura Biosciences 的目標價格設定為 25.00 美元。花旗集團在 3 月 26 日（星期三）的研究報告中重申了對 Aura Biosciences 的 “跑贏大盤” 評級。最後，Lifesci Capital 在 1 月 31 日（星期五）的研究報告中將 Aura Biosciences 的評級提升至 “強力買入”。六位研究分析師對該股票給予了買入評級，兩位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，Aura Biosciences 目前的共識評級為 “買入”，共識目標價格為 22.75 美元。</p>
<p><strong>閲讀我們對 Aura Biosciences 的最新分析</strong></p>
<h2>關於 Aura Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Aura Biosciences, Inc.是一家臨牀階段的生物技術公司，開發精準免疫療法以治療多種實體腫瘤。該公司的專有平台能夠通過與藥物結合或裝載核酸的類病毒顆粒，針對多種實體腫瘤，創造類病毒藥物結合物。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Aura Biosciences</li>
<li>使用 MarketBeat 股票拆分計算器</li>
<li>Viking Therapeutics 股票上漲但難以保持漲幅</li>
<li>市值計算器：如何計算市值</li>
<li>高通股票剛剛獲得新的買入評級——值得期待</li>
<li>什麼是熱門股票？熱門股票的解釋</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Aura Biosciences 嗎？</h2>
<p>在考慮 Aura Biosciences 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Aura Biosciences 並不在名單上。</p>
<p>雖然 Aura Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

AURA

<p>Aura Biosciences, Inc. 的內部人士 Conor Kilroy 以每股 5.49 美元的價格出售了 7,162 股，總計 39,319.38 美元，減少了 3.84% 的持股比例。出售後，他持有 179,313 股，估值約為 984,428.37 美元。該股票下跌 3.1%，報 5.40 美元，市值為 2.7122 億美元。分析師設定的共識目標價為 22.75 美元，大多數分析師給予該股票 “買入” 評級</p>

<p>Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Conor Kilroy sold 7,162 shares of the company's stock in a transaction dated Wednesday, April 16th. The stock was sold at an average price of $5.49, for a total value of $39,319.38. Following the sale, the insider now owns 179,313 shares of the company's stock, valued at $984,428.37. This represents a 3.84 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Aura Biosciences, Inc.（納斯達克代碼：AURA - 獲取免費報告）內部人士 Conor Kilroy 於 4 月 16 日（星期三）出售了 7,162 股公司股票。該股票以平均價格 5.49 美元出售，總價值為 39,319.38 美元。出售後，該內部人士現在持有 179,313 股公司股票，價值為 984,428.37 美元。這代表其持股比例下降了 3.84%。此次出售已在與證券交易委員會的法律文件中披露，您可以通過此鏈接訪問。</p>
</div><p>Get <strong>Aura Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Aura Biosciences</strong> 警報：</p>
</div><h2>Aura Biosciences Trading Down 3.1 %</h2>
<div class="lb-trans"><h2>Aura Biosciences 股價下跌 3.1%</h2>
</div><ul>
<li>3 Small-Cap Stocks Ready to Deliver Significant Growth</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小盤股準備實現顯著增長</li>
</ul>
</div><p>NASDAQ:AURA traded down $0.17 during trading hours on Wednesday, hitting $5.40. The stock had a trading volume of 138,043 shares, compared to its average volume of 200,409. The business has a 50 day simple moving average of $6.85 and a two-hundred day simple moving average of $8.23. Aura Biosciences, Inc. has a 1-year low of $3.40 and a 1-year high of $12.38. The company has a market cap of $271.22 million, a PE ratio of -3.12 and a beta of 0.43.</p>
<div class="lb-trans"><p>在週三的交易時段，納斯達克：AURA 股價下跌 0.17 美元，跌至 5.40 美元。該股票的交易量為 138,043 股，而其平均交易量為 200,409 股。該公司的 50 日簡單移動平均為 6.85 美元，200 日簡單移動平均為 8.23 美元。Aura Biosciences, Inc.的 1 年最低價為 3.40 美元，1 年最高價為 12.38 美元。該公司的市值為 2.7122 億美元，市盈率為-3.12，貝塔值為 0.43。</p>
</div><p>Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). Research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Aura Biosciences（納斯達克：AURA - 獲取免費報告）最近於 3 月 24 日（星期一）發佈了季度財報。該公司報告季度每股收益（EPS）為-0.52 美元，低於市場共識預期的-0.43 美元，差距為-0.09 美元。研究分析師預計 Aura Biosciences, Inc.在當前財政年度將發佈-1.66 的每股收益。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently modified their holdings of the business. Long Focus Capital Management LLC increased its holdings in Aura Biosciences by 123.9% during the 4th quarter. Long Focus Capital Management LLC now owns 2,537,774 shares of the company's stock worth $20,861,000 after purchasing an additional 1,404,228 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Aura Biosciences by 6.2% during the fourth quarter. Vanguard Group Inc. now owns 1,917,730 shares of the company's stock worth $15,764,000 after buying an additional 112,296 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Aura Biosciences by 3.2% during the fourth quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock worth $14,164,000 after buying an additional 54,103 shares in the last quarter. Levin Capital Strategies L.P. increased its stake in shares of Aura Biosciences by 169.1% in the fourth quarter. Levin Capital Strategies L.P. now owns 1,247,619 shares of the company's stock worth $10,255,000 after buying an additional 783,984 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Aura Biosciences by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after acquiring an additional 3,972 shares in the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近調整了對該公司的持股。Long Focus Capital Management LLC 在第四季度將其在 Aura Biosciences 的持股增加了 123.9%。Long Focus Capital Management LLC 現在擁有 2,537,774 股公司股票，價值 20,861,000 美元，在上個季度購買了 1,404,228 股。Vanguard Group Inc.在第四季度將其在 Aura Biosciences 的持股增加了 6.2%。Vanguard Group Inc.現在擁有 1,917,730 股公司股票，價值 15,764,000 美元，在上個季度購買了 112,296 股。Franklin Resources Inc.在第四季度將其在 Aura Biosciences 的持股增加了 3.2%。Franklin Resources Inc.現在擁有 1,723,063 股公司股票，價值 14,164,000 美元，在上個季度購買了 54,103 股。Levin Capital Strategies L.P.在第四季度將其在 Aura Biosciences 的持股增加了 169.1%。Levin Capital Strategies L.P.現在擁有 1,247,619 股公司股票，價值 10,255,000 美元，在上個季度購買了 783,984 股。最後，Geode Capital Management LLC 在第四季度將其在 Aura Biosciences 的持股增加了 0.4%。Geode Capital Management LLC 現在擁有 1,012,799 股公司股票，價值 8,327,000 美元，在上個季度購買了 3,972 股。機構投資者和對沖基金持有該公司 96.75% 的股票。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>A number of analysts have recently issued reports on the company. JMP Securities set a $19.00 target price on Aura Biosciences in a report on Wednesday, March 26th. HC Wainwright set a $25.00 price objective on shares of Aura Biosciences in a research note on Tuesday, March 25th. Citigroup reissued an &#34;outperform&#34; rating on shares of Aura Biosciences in a research note on Wednesday, March 26th. Finally, Lifesci Capital raised shares of Aura Biosciences to a &#34;strong-buy&#34; rating in a research report on Friday, January 31st. Six research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, Aura Biosciences presently has a consensus rating of &#34;Buy&#34; and a consensus target price of $22.75.</p>
<div class="lb-trans"><p>一些分析師最近對該公司發佈了報告。JMP Securities 在 3 月 26 日（星期三）的報告中將 Aura Biosciences 的目標價格設定為 19.00 美元。HC Wainwright 在 3 月 25 日（星期二）的研究報告中將 Aura Biosciences 的目標價格設定為 25.00 美元。花旗集團在 3 月 26 日（星期三）的研究報告中重申了對 Aura Biosciences 的 “跑贏大盤” 評級。最後，Lifesci Capital 在 1 月 31 日（星期五）的研究報告中將 Aura Biosciences 的評級提升至 “強力買入”。六位研究分析師對該股票給予了買入評級，兩位分析師給予了強力買入評級。根據 MarketBeat.com 的數據，Aura Biosciences 目前的共識評級為 “買入”，共識目標價格為 22.75 美元。</p>
</div><p><strong>Read Our Latest Analysis on Aura Biosciences</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Aura Biosciences 的最新分析</strong></p>
</div><h2>About Aura Biosciences</h2>
<div class="lb-trans"><h2>關於 Aura Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.</p>
<div class="lb-trans"><p>Aura Biosciences, Inc.是一家臨牀階段的生物技術公司，開發精準免疫療法以治療多種實體腫瘤。該公司的專有平台能夠通過與藥物結合或裝載核酸的類病毒顆粒，針對多種實體腫瘤，創造類病毒藥物結合物。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Aura Biosciences</li>
<li>Using the MarketBeat Stock Split Calculator</li>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
<li>Market Cap Calculator: How to Calculate Market Cap</li>
<li>Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited</li>
<li>What Are Trending Stocks? Trending Stocks Explained</li>
<li>Meta Stock Holds Upside Potential as Analysts Cut Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Aura Biosciences</li>
<li>使用 MarketBeat 股票拆分計算器</li>
<li>Viking Therapeutics 股票上漲但難以保持漲幅</li>
<li>市值計算器：如何計算市值</li>
<li>高通股票剛剛獲得新的買入評級——值得期待</li>
<li>什麼是熱門股票？熱門股票的解釋</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVVSQQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AURA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對該故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aura Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Aura Biosciences 嗎？</h2>
</div><p>Before you consider Aura Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Aura Biosciences 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aura Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Aura Biosciences 並不在名單上。</p>
</div><p>While Aura Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Aura Biosciences 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Aura Biosciences, Inc. (NASDAQ:AURA) 的內部人士 Conor Kilroy 出售了 7,162 股股票